RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Eye & ENT Hospital of Fudan University; 6 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Pathologically diagnosed with recurrent nasopharyngeal carcinoma;

    Inclusion criterion 1

  3. Resectable disease staging rT2 (deep parapharyngeal space, or distance to the internal carotid ≤5mm) or rT3 (excluding the lesions confined to the basal wall of sphenoid sinus), rT4, according to AJCC 8th edition;

    Inclusion criterion 2

  4. ≥6months from the accomplishment of radical radiation to recurrence

    Inclusion criterion 7

    previously only 1 course of radiotherapy;

    Inclusion criterion 8

  5. ECOG score 0-2 and can tolerate surgery,chemotherapy and immunotherapy.

    Inclusion criterion 10

  6. Suffering from another or multiple malignancy within 5 years (excluding fully treated basal cell or skin squamous cell carcinoma, cervical carcinoma in situ, etc.);

    Exclusion criterion 3

  7. Female patients who are at pregnancy or lactation;

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06235203, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Pathologically diagnosed with recurrent nasopharyngeal carcinoma;
  • Resectable disease staging rT2 (deep parapharyngeal space, or distance to the internal carotid ≤5mm) or rT3 (excluding the lesions confined to the basal wall of sphenoid sinus), rT4, according to AJCC 8th edition;
  • Cervical lymph node metastasis can be controlled locally;
  • Aged 18 to 75 years;
  • Informed consent forms signed to participate in the trial;
  • Without distant metastasis;
  • ≥6months from the accomplishment of radical radiation to recurrence
  • previously only 1 course of radiotherapy;
  • Sufficient organ function;
  • ECOG score 0-2 and can tolerate surgery,chemotherapy and immunotherapy.

Exclusion Criteria:

  • Participate in other interventional clinical trials;
  • Uncontrolled illnesses that interfere with the therapy;
  • Suffering from another or multiple malignancy within 5 years (excluding fully treated basal cell or skin squamous cell carcinoma, cervical carcinoma in situ, etc.);
  • Any contradiction to surgery;
  • With serious autoimmune disease;
  • The patient is currently using immunosuppressive agents or systemic hormone therapy to achieve immunosuppressive effects (dosage>10mg/day prednisone or other glucocorticoids), and continues to use them within 2 weeks before the first administration;
  • Severe allergic reactions to other monoclonal antibodies;
  • History of radioactive particle planting;
  • Vaccination with live vaccine within 4 weeks prior to initial administration or possibly during the study period;
  • Female patients who are at pregnancy or lactation;
  • Other situations that the researchers believe not suitable for enrollment

Quoted from ClinicalTrials.gov, NCT06235203, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06235203, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06235203